Prothena's stock surged nearly 40% after promising results from a midstage study of its Parkinson's treatment, prasinezumab, partnered with Roche. Although the drug missed its primary goal, it showed a delay in motor worsening, particularly in patients using levodopa, suggesting potential for future trials. Analysts estimate Prothena could earn up to $275 million in royalties, despite concerns about the drug's modest efficacy and administration challenges.
biotech stocks show resilience as top companies report strong earnings
Biotech stocks have shown resilience, with Corcept Therapeutics leading the sector, reporting strong earnings and a robust pipeline. Harmony Biosciences focuses on its narcolepsy treatment, while ADMA Biologics faces challenges after an auditor's resignation. Ligand Pharmaceuticals and United Therapeutics also maintain strong positions, with significant sales growth and promising pipelines.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.